Bleeding time (BT) and hemodynamic effects of deshopressin (DDAVP) in patients with cirrhosis

Lopez, P. O.; Mastaï, Ricardo; Otaso, Jc.; Alvarez, David Bouza; Rojter, Sergio; Podestá, A; Romero, Gustavo

doi:10.1016/0168-8278(91)91169-h

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FVIII and VWF are in the high normal range, or even higher in these patients, yet both i.v. and s.c. desmopressin shortens the bleeding time of cirrhotic patients [9][10][11][12]. Hence, desmopressin is a possible prophylactic treatment for cirrhotics who have a prolonged bleeding time and need invasive diagnostic procedures.…”

Section: Acquired and Drug-induced Disorders Of Haemostasismentioning

confidence: 99%

The use of desmopressin in open‐heart surgery

Cattaneo

2007

Haemophilia

View full text Add to dashboard Cite

Desmopressin (l-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analogue of the antidiuretic hormone vasopressin. Like the natural antidiuretic hormone, desmopressin increases the plasma levels of factor VIII and von Willebrand factor (vWF), with the advantage, compared to vasopressin, that it produces little or no vasoconstriction, no increase in blood pressure, and no contraction of the uterus or gastrointestinal tract, so that it is well tolerated when administered to humans. In 1977, desmopressin was used for the first time in patients with mild hemophilia A and von Willebrand disease (vWD) for the prevention and treatment of bleeding, first during dental extractions and then during major surgical procedures. The clinical indications for desmopressin rapidly expanded beyond hemophilia and vWD. The compound was shown to be efficacious even in bleeding disorders not involving a deficiency or dysfunction of factor VIII or vWF, including congenital and acquired defects of platelet function and such frequent abnormalities of hemostasis as those associated with chronic kidney and liver diseases. Desmopressin has also been used prophylactically in patients undergoing surgical operations characterized by large blood loss and transfusion requirements.

show abstract

Section: Acquired and Drug-induced Disorders Of Haemostasismentioning

confidence: 99%

The use of desmopressin in open‐heart surgery

Cattaneo

2007

Haemophilia

View full text Add to dashboard Cite

show abstract

“…It has been reported that DDAVP has shortened prolonged bleeding time in human patients with aspirin-induced platelet dysfunction and prolonged bleeding time and activated partial thromboplastin time (APTT) in human cases of chronic liver diseases [1,3,8,11,13,14]. Therefore, DDAVP has expected to be useful during biopsy or surgical procedures in aspirin-administrated patients and patients with chronic liver diseases.…”

mentioning

confidence: 99%

Effects of DDAVP Administrated Subcutaneously in Dogs with Aspirin-induced Platelet Dysfunction and Hemostatic Impairment due to Chronic Liver Diseases.

Sakai

Watari

Miura

et al. 2003

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. To evaluate the hemostatic effects of desmopressin (DDAVP) in dogs with aspirin-induced platelet dysfunction and hemostatic impairment in chronic liver diseases, 3 µg/kg DDAVP was administrated subcutaneously. In aspirin-induced platelet dysfunction dogs (n=5), prolonged BMBT (buccal mucosal bleeding time) was shortened significantly after DDAVP injection (2.2 ± 1.2 min, P<0.05). In dogs with chronic liver diseases (n=4), activated partial thromboplastin time (APTT) tended to shorten by 0.9 to 3.0 sec, and prolonged BMBT was shortened in two cases for 4.2 and 1.7 min after DDAVP injection. Therefore, the present results indicated that DDAVP shortened the prolonged BMBT in dogs with aspirin-induced platelet dysfunction and chronic liver disease. DDAVP might be helpful in hemostasis under invasive procedures such as biopsy or surgery for dogs with hemostatic impairment. KEY WORDS: aspirin-induced platelet dysfunction, canine, chronic liver disease, DDAVP, hemostasis.

show abstract

“…diameter of portal vein (DPV), velocity of portal vein (PVV), volume of portal blood flow (PVF) and hepatic artery pulsatility index (HA‐PI) – than hepatic vein catheterisation. Because it is a useful non‐invasive tool in detecting portal hypertension and may provide information about the morphology and haemodynamics of portal hypertension, it has recently been used to study the haemodynamic effect of the vasopressin analogue 9,10 . However, it has not been used to measure the hepatic and systemic haemodynamics of somatostatin or octreotide in the treatment of variceal bleeding.…”

mentioning

confidence: 99%

Effects of Somatostatin, Octreotide and Pitressin Plus Nitroglycerine on Systemic and Portal Haemodynamics in the Control of Acute Variceal Bleeding

Zhang

Wong

Zhou

et al. 2002

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYTo examine the haemodynamic effects of somatostatin (SS) and octreotide (OC) versus pitressin plus nitroglycerine (PN) in the control of variceal bleeding, 224 patients with acute oesophageal and gastric variceal haemorrhage were randomly divided into three groups and treated with SS, OC and PN; they also had their Doppler ultrasound parameters measured before, during and after treatment. The success rates of bleeding control in the SS (80.9%, 86.8% and 89.7%, p<0.001) and OC (75.3%, 80.8% and 84.9%, p<0.01) groups were significantly higher than in the PN group (51.8%, 59.0% and 65.1%) at 24, 48 and 72 hours respectively, and the average duration of SS (12.7 + 6.8 h) and OC (13.8 + 8.0 h) was significantly lower than that of PN (24.6 + 15.4 h, p<0.001). Side‐effects of SS (7.4%) and OC (8.2%) were less than those of PN (41.0%, p<0.001 and p<0.01). The diameter of portal vein (PVD), velocity of portal vein (PVV), volume of portal blood flow (PVF) and hepatic artery pulsatility index (HA‐PI) in all three groups decreased significantly during initial treatment, but recovered when treatment was stopped. Heart rate and cardiac output decreased significantly in patients treated with SS and OC; mean arterial pressure was unchanged. However, heart rate and mean arterial pressure increased, and cardiac output decreased, with PN. Somatostatin and octreotide were more effective than pitressin plus nitroglycerine in patients with acute variceal haemorrhage, with fewer side‐effects, and may decrease PVF and portal vein pressure through reduction of cardiac output and dilatation of the visceral blood vessels.

show abstract

Bleeding time (BT) and hemodynamic effects of deshopressin (DDAVP) in patients with cirrhosis

Cited by 3 publications

References 0 publications

The use of desmopressin in open‐heart surgery

The use of desmopressin in open‐heart surgery

Effects of DDAVP Administrated Subcutaneously in Dogs with Aspirin-induced Platelet Dysfunction and Hemostatic Impairment due to Chronic Liver Diseases.

Effects of Somatostatin, Octreotide and Pitressin Plus Nitroglycerine on Systemic and Portal Haemodynamics in the Control of Acute Variceal Bleeding

Contact Info

Product

Resources

About